Funding for this research was provided by:
Paracelsus Medical University
Article History
Received: 15 May 2021
Accepted: 9 June 2021
First Online: 16 August 2021
Conflict of interest
: <i>Employment or Leadership Position:</i> None; <i>Consultant or Advisory Role:</i> S. P. Gampenrieder for Pfizer, Novartis, Eli Lilly; G. Rinnerthaler for Pfizer, Novartis, Eli Lilly; R. Greil for Novartis; <i>Stock Ownership:</i> None; <i>Speakers Honoraria:</i> S. P. Gampenrieder from Novartis; Rinnerthaler from Novartis; R. Greil from Novartis; <i>Travel Grants:</i> S. P. Gampenrieder from, Novartis, Pfizer; G. Rinnerthaler from Novartis, Pfizer; <i>Research Funding:</i> R. Greil from Novartis (no personal payments).